Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leishmanolysin-like peptidase (LMLN) is a zinc-dependent metallopeptidase of the M8 family, encoded by the LMLN gene on human chromosome 3[1][3][5]. The protein is found in ring-like structures similar to invadopodia and is relocalized from intracellular sites to the leading edge in migrating cells, suggesting a role in cell migration and tissue invasion[5]. In Drosophila, a similar protein (“invadolysin”) has been implicated in mitotic progression, hinting at conserved cellular functions[1]. The best-characterized homolog, GP63, is a major surface protease and virulence factor in Leishmania parasites, where it contributes to pathogenicity and immune evasion; in humans, the precise physiological and pathophysiological roles of LMLN remain to be fully elucidated, but its molecular features indicate a likely involvement in processes requiring cell motility and invasion[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leishmanolysin-like peptidase (LMLN).